Brodalumab Efficacy in Psoriasis Patients with Inadequate Response to IL-23 or IL-12/23 Inhibitors: Multicenter Italian Retrospective Analysis - IL PSO (Italian Landscape Psoriasis).
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Orsini Diego, Fargnoli Maria Concetta, Burlando Martina, Campanati Anna, Campione Elena, Guarneri Claudio, Narcisi Alessandra, Pella Paolo, Romita Paolo, Travaglini Massimo, Zichichi Leonardo, Arancio Luisa Maria Halina, Assorgi Chiara, Baggini Ginevra, Balestri Riccardo, Bianchi Luca, Brunasso Alexandra Maria Giovanna, Cagni Anna Elisabetta, Caldarola Giacomo, Calianno Gianluca, Carpentieri Antonio, Carriero Martino, Carugno Andrea, Cona Franco, Costanzo Antonio, Cozzani Emanuele, Bello Giacomo Dal, Dapavo Paolo, Dattola Annunziata, Di Tano Antonio, Diotallevi Federico, Donnarumma Marianna, De Col Elena, Esposito Maria, Fiorella Carmen Silvia, Galluzzo Marco, Graziola Francesca, Danzuso Giovanni Carlo Lazzaro, Licciardello Matteo, Legori Agostina, Lora Viviana, Malagoli Piergiorgio, Megna Matteo, Mola Federica, Moretta Gaia, Muracchioli Andrea, Musumeci Attilia, Musumeci Maria Letizia, Pagnanelli Gianluca, Panasiti Vincenzo, Provenzano Eugenio, Ribero Simone, Rizzo Daniele, Rubatto Marco, Sarno Oriele, Strippoli Davide, Vaira Fabrizio, Graceffa Dario
Аннотация
OBJECTIVES: To evaluate the safety and the efficacy of brodalumab in a subgroup of psoriasis patients who already failed anti-IL23 or anti-IL12/23 treatment.
METHODS: Using the Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI), we retrospectively evaluated a cohort of 23 patients with psoriasis who underwent a change in therapy with brodalumab exclusively following primary or secondary therapeutic failure of anti-IL-23 or anti-12/23 drugs.
RESULTS: The mean PASI decreased significantly following the introduction of brodalumab after four weeks of treatment, continuing to decrease at 16 and 36 weeks, reaching the nadir at 52 weeks (baseline PASI baseline: 14.6 ± 9.2 vs. 52 weeks PASI: 1.1 ± 1.8; P<0.001). Sixty-three point six percent of patients reached PASI 100 just after 16 weeks. The same trend of improvement was also observed for the DLQI. The adverse effects observed in our study population were generally mild.
CONCLUSIONS: Our results are in line with the current literature and suggest that patients who have failed therapy with IL-23 or IL-12/23 inhibitors may benefit from switching to brodalumab, which could be considered a good choice for patients who need a rapid resolution of the inflammatory skin condition.